Navigation Links
ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium
Date:1/22/2009

IRVINE, Calif., Jan. 22 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced positive results from the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye disease. Patients treated with ecabet sodium achieved a strong positive trend in the objective sign of Tear Film Break-Up Time (TFBUT) and a positive trend in the objective sign of quantity of tears produced (Schirmer Test). In contrast, there were no trends seen in the placebo group for either objective sign. In addition, there were no trends seen in either group in subjective symptoms as measured by the Ocular Surface Disease Index (OSDI) or patient's worst reported symptom. In Phase II tests where observations are not powered to show statistical significance, strong and positive trends are used as indicators of potential efficacy in subsequent Phase III studies.

"The Phase IIb results from this environmental study add further support to our belief that ecabet sodium has the ability to treat signs and symptoms of dry eye syndrome. Ecabet sodium may provide advantages over other products used to treat dry eye and those that are in development, as we believe ecabet sodium not only improves the quality of tears but also increases the quantity of tears," stated Vicente Anido Jr., Ph.D., President and Chief Executive Officer of ISTA Pharmaceuticals. "After reviewing the guidance from and our discussions with the FDA, we believe that by conducting two successful Phase III environmental clinical trials for improvement in signs and two successful Phase III controlled chamber clinical trials for the improvement of symptoms, we should receive marketing approval. In addition, we are expecting results from a Phase II clinical trial studying the potential of a lower strength of Xibrom to treat the signs and symptoms
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ISTA Pharmaceuticals New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in Second of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
4. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
5. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
6. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
7. Cylene Pharmaceuticals Initiates Phase I Trial With CX-4945 -Breakthrough First-in Class Inhibitor of CK2
8. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
9. Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 ... convened in Boston on July ... in an effort to more fully exploit the potential ... applied to brain diseases. "As an established ... a responsibility to assume a leadership role - in ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, Inc., ... treatment of cancer, today announced that Rachel ... company,s Board of Directors, has been appointed chief ... Eli Lilly and AstraZeneca, and also oversaw clinical ... checkpoint inhibitor, at Bristol-Myers Squibb and the development ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015 Oryzon today ... Renshaw 17th Annual Global Investment Conference in New ... ORYZON will be represented by President and CEO Carlos ... Dr. Buesa will present this information on Thursday September 10, ... Floor).  The company is completing preclinical development of its ORY-2001 ...
Breaking Medicine Technology:New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 2New Elekta Consortium to Push Frontiers of Linear Accelerator-Based Stereotactic Radiation Therapy for the Brain 3Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 3ORYZON to Present at Rodman & Renshaw 17th Annual Global Investment Conference 4
... to Educate Women About this Common Condition, MILWAUKEE, ... at the Hyatt Regency Milwaukee hotel (333 West Kilbourn ... 7:30 pm to talk about her,experience with stress urinary ... Down There?: Breaking the Ice About SUI, a,national public ...
... Opiate-Like Side Effects For Several ... Months Following a Single Administration, SOUTH SAN FRANCISCO, Calif., ... that it has initiated a new,Phase 2 study of Adlea(TM) ... total knee replacement surgery, also called,total knee arthroplasty (TKA). Adlea ...
Cached Medicine Technology:Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 2Bonnie Blair to Break the Ice About Stress Urinary Incontinence in Milwaukee 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 2Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 3Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery 4
(Date:8/27/2015)... Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Association and the American Heart Association have released new guidelines to educate doctors and ... the last update to these particular guidelines came in 2007, so the new version ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Thriveology Founders, ... the featured speakers at The Amazing Aging Expo in Denver, Colorado on Saturday, August ... doctors are consistently featured in media outlets as health authorities, and will present a ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... the exploding legal marijuana industry with the launch of its Doobster platform, a ... marijuana to order products from their smart phones and tablets. Well, Doobster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of mothers ... Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and causing ... University study. , While most people don’t develop persistent depression after a major ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
... ... in Ophthalmology (JCAHPO), and the Association of Technical Personnel in Ophthalmology (ATPO) proudly launched ... Reference Guide for the Ophthalmic Technician. , ... St. Paul, MN (Vocus) November 10, 2009 -- Compact, ...
... HATBORO, Pa., Nov. 10 InfoLogix, Inc. (Nasdaq: ... solutions for the healthcare and commercial industries, today announced ... exception to NASDAQ,s stockholder approval requirements, in accordance with ... on this exception to complete a proposed plan of ...
... ... Arm in the Last 30 Years" , ... Gulf Breeze, Fla. (Vocus) November 10, 2009 -- The Andrews-Paulos Research & ... Rounds presentation on November, 19, 2009 at 5:30 p.m. (CT). Renowned orthopaedic and sports ...
... Better coordination urged to stem re-admission rate of nearly 1 ... Almost a quarter of the people on Medicare who are ... a month of discharge, a new study reveals. , That ... assistant professor of geriatrics and palliative medicine at the Mount ...
... YORK Medications frequently given to cancer patients to ... increased risk of deep vein thrombosis or pulmonary embolism, ... M.S., co-director of the breast cancer program at the ... Medical Center. The findings will be published online on ...
... Amalgamated Capital, a newly formed division of Amalgamated ... in the recapitalization of Oklahoma City-based 180 Medical, Inc., ... Amalgamated Capital provides senior cash flow debt financing to ... firms and other investors are financial sponsors. , 180 ...
Cached Medicine News:Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 2Health News:JCAHPO/ATPO Pocket Guide Launches for Eye Care Professionals 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 2Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 3Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 4Health News:InfoLogix Announces Receipt of NASDAQ Waiver for Stockholder Approval of Restructuring and Extension to Stockholder's Equity Requirement 5Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 2Health News:Orthopaedic Surgeon and AOSSM President Dr. James Andrews to Discuss Injury Prevention 3Health News:The Revolving Door of Heart Failure Hospitalization 2Health News:The Revolving Door of Heart Failure Hospitalization 3Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 2Health News:Drugs to treat anemia in cancer patients linked to thromboembolism 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 2Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 3Health News:Amalgamated Capital Serves as Syndication Agent in the Recapitalization of 180 Medical, Inc. 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: